Toms_2020_J.Nucl.Med_61_1806

Fibroblast activation protein (FAP) has emerged as an interesting molecular target used in the imaging and therapy of various types of cancers. (68)Ga-labeled chelator-linked FAP inhibitors (FAPIs) have been successfully applied to PET imaging of various tumor types. To broaden the spectrum of applicable PET tracers for extended imaging studies of FAP-dependent diseases, we herein report the radiosynthesis and preclinical evaluation of an (18)F-labeled glycosylated FAPI ([(18)F]FGlc-FAPI). Methods: An alkyne-bearing precursor was synthesized and subjected to click chemistry-based radiosynthesis of [(18)F]FGlc-FAPI by 2-step (18)F-fluoroglycosylation. FAP-expressing HT1080hFAP cells were used to study competitive binding to FAP, cellular uptake, internalization, and efflux of [(18)F]FGlc-FAPI in vitro. Biodistribution studies and in vivo small-animal PET studies of [(18)F]FGlc-FAPI compared with [(68)Ga]Ga-FAPI-04 were conducted in nude mice bearing HT1080hFAP tumors or U87MG xenografts. Results: [(18)F]FGlc-FAPI was synthesized with a 15% radioactivity yield and a high radiochemical purity of more than 99%. In HT1080hFAP cells, [(18)F]FGlc-FAPI showed specific uptake, a high internalized fraction, and low cellular efflux. Compared with FAPI-04 (half maximal inhibitory concentration [IC(50)] = 32 nM), the glycoconjugate, FGlc-FAPI (IC(50) = 167 nM), showed slightly lower affinity for FAP in vitro, whereas plasma protein binding was higher for [(18)F]FGlc-FAPI. Biodistribution studies revealed significant hepatobiliary excretion of [(18)F]FGlc-FAPI; however, small-animal PET studies in HT1080hFAP xenografts showed higher specific tumor uptake of [(18)F]FGlc-FAPI (4.5 percentage injected dose per gram of tissue [%ID/g]) than of [(68)Ga]Ga-FAPI-04 (2 %ID/g). In U87MG tumor-bearing mice, both tracers showed similar tumor uptake, but [(18)F]FGlc-FAPI showed a higher tumor retention. Interestingly, [(18)F]FGlc-FAPI demonstrated high specific uptake in bone structures and joints. Conclusion: [(18)F]FGlc-FAPI is an interesting candidate for translation to the clinic, taking advantage of the longer half-life and physical imaging properties of (18)F. The availability of [(18)F]FGlc-FAPI may allow extended PET studies of FAP-related diseases, such as cancer, but also arthritis, heart diseases, or pulmonary fibrosis.